195 related articles for article (PubMed ID: 24747966)
1. Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo.
Greenall SA; Donoghue JF; Gottardo NG; Johns TG; Adams TE
Oncogene; 2015 Mar; 34(13):1658-66. PubMed ID: 24747966
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Sepúlveda-Sánchez JM; Vaz MÁ; Balañá C; Gil-Gil M; Reynés G; Gallego Ó; Martínez-García M; Vicente E; Quindós M; Luque R; Ramos A; Ruano Y; Pérez-Segura P; Benavides M; Sánchez-Gómez P; Hernández-Laín A
Neuro Oncol; 2017 Oct; 19(11):1522-1531. PubMed ID: 28575464
[TBL] [Abstract][Full Text] [Related]
5. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T; Tachihara M; Nishimura Y
Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.
Lu C; Mi LZ; Schürpf T; Walz T; Springer TA
J Biol Chem; 2012 Nov; 287(45):38244-53. PubMed ID: 22988250
[TBL] [Abstract][Full Text] [Related]
7. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
[TBL] [Abstract][Full Text] [Related]
8. Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation.
Ymer SI; Greenall SA; Cvrljevic A; Cao DX; Donoghue JF; Epa VC; Scott AM; Adams TE; Johns TG
Cancers (Basel); 2011 Apr; 3(2):2032-49. PubMed ID: 24212795
[TBL] [Abstract][Full Text] [Related]
9. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.
Zhu Y; Shah K
Cancer Biol Ther; 2014 Jun; 15(6):815-22. PubMed ID: 24658109
[TBL] [Abstract][Full Text] [Related]
10. Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.
Jin P; Zhang J; Beryt M; Turin L; Brdlik C; Feng Y; Bai X; Liu J; Jorgensen B; Shepard HM
Mol Med; 2009; 15(1-2):11-20. PubMed ID: 19048033
[TBL] [Abstract][Full Text] [Related]
11. A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.
Endersby R; Whitehouse J; Hii H; Greenall SA; Johns TG; Gottardo NG
Neoplasia; 2018 May; 20(5):432-442. PubMed ID: 29574250
[TBL] [Abstract][Full Text] [Related]
12. Dacomitinib: an investigational drug for the treatment of glioblastoma.
Sepúlveda JM; Sánchez-Gómez P; Vaz Salgado MÁ; Gargini R; Balañá C
Expert Opin Investig Drugs; 2018 Oct; 27(10):823-829. PubMed ID: 30247945
[TBL] [Abstract][Full Text] [Related]
13. Effect of phosphorylation on EGFR dimer stability probed by single-molecule dynamics and FRET/FLIM.
Coban O; Zanetti-Dominguez LC; Matthews DR; Rolfe DJ; Weitsman G; Barber PR; Barbeau J; Devauges V; Kampmeier F; Winn M; Vojnovic B; Parker PJ; Lidke KA; Lidke DS; Ameer-Beg SM; Martin-Fernandez ML; Ng T
Biophys J; 2015 Mar; 108(5):1013-26. PubMed ID: 25762314
[TBL] [Abstract][Full Text] [Related]
14. Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma.
Greenall SA; McKenzie M; Seminova E; Dolezal O; Pearce L; Bentley J; Kuchibhotla M; Chen SC; McDonald KL; Kornblum HI; Endersby R; Adams TE; Johns TG
Neuro Oncol; 2019 Aug; 21(8):1016-1027. PubMed ID: 31002307
[TBL] [Abstract][Full Text] [Related]
15. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Lau SCM; Batra U; Mok TSK; Loong HH
Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718
[TBL] [Abstract][Full Text] [Related]
16. Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain.
Ozer BH; Wiepz GJ; Bertics PJ
Oncogene; 2010 Feb; 29(6):855-64. PubMed ID: 19915609
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.
Zahonero C; Aguilera P; Ramírez-Castillejo C; Pajares M; Bolós MV; Cantero D; Perez-Nuñez A; Hernández-Laín A; Sánchez-Gómez P; Sepúlveda JM
Mol Cancer Ther; 2015 Jul; 14(7):1548-58. PubMed ID: 25939761
[TBL] [Abstract][Full Text] [Related]
18. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.
Park AK; Francis JM; Park WY; Park JO; Cho J
Oncotarget; 2015 Apr; 6(11):8839-50. PubMed ID: 25826094
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
[TBL] [Abstract][Full Text] [Related]
20. Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.
Jathal MK; Steele TM; Siddiqui S; Mooso BA; D'Abronzo LS; Drake CM; Whang YE; Ghosh PM
Br J Cancer; 2019 Jul; 121(3):237-248. PubMed ID: 31209328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
